Status:
RECRUITING
Study of MAR002 in Healthy Men
Lead Sponsor:
Marea Therapeutics
Conditions:
Acromegaly
Eligibility:
MALE
18-40 years
Phase:
PHASE1
Brief Summary
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
Eligibility Criteria
Inclusion
- Willingness to provide written informed consent
- Age 18 to 40
- Weight 55 to 95 kg
- Body mass index (BMI) 18 to 30 kg/m2
- Healthy men
Exclusion
- History of hypersensitivity to monoclonal antibodies or study drug
- Participation in any other investigational drug study
- History of cancer
- Recent acute illness
- Positive test for HIV, hepatitis B/C
- History of substance abuse or nicotine use
- Recent blood donation
- History of pituitary disorder
- Any condition that prevents the participant from complying with study procedures
Key Trial Info
Start Date :
August 11 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT07195175
Start Date
August 11 2025
End Date
May 1 2026
Last Update
September 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marea Site
Tempe, Arizona, United States, 85283